Long-Term Bets: Kalpataru, Aurobindo Pharma Eyed for 20-40% Returns by 2026

Brokerage firms have identified five Indian stocks, including Kalpataru Projects International and Aurobindo Pharma, as potential long-term investments with expected returns of 20-40% by 2026. This indicates a positive outlook from analysts on these specific companies.

Such recommendations from top brokerage firms can influence investor sentiment and capital allocation, particularly for long-term portfolios. While the market has likely absorbed this information, it signals underlying growth potential in these companies and their respective sectors, which could attract further institutional interest.

Kalpataru Projects International (KPIL) and Aurobindo Pharma (AUROPHARMA) are directly impacted positively by these recommendations, potentially seeing sustained investor interest. Other unnamed stocks in the list would also benefit. The broader infrastructure and pharmaceutical sectors could also see a halo effect, attracting attention to peers.

Traders should monitor the performance of these recommended stocks against their projected returns. Look for any new analyst upgrades or downgrades, quarterly earnings reports, and sector-specific developments that could confirm or contradict these long-term growth projections. Fresh technical analysis is crucial for entry points.

• •List of recommendations from top brokerage firms collated.
• •Kalpataru and Aurobindo Pharma are among 5 stocks mentioned.
• •Stocks could give 20-40% return by 2026.
• •Recommendations are for long-term investment.